Shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Free Report) were down 7.8% during trading on Friday . The stock traded as low as $0.3044 and last traded at $0.3044. Approximately 100 shares traded hands during trading, a decline of 100% from the average daily volume of 34,430 shares. The stock had previously closed at $0.33.
Anebulo Pharmaceuticals Stock Performance
The business’s fifty day moving average price is $0.36 and its two-hundred day moving average price is $0.53. The firm has a market capitalization of $12.41 million, a P/E ratio of -1.60 and a beta of -1.82.
Hedge Funds Weigh In On Anebulo Pharmaceuticals
An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. purchased a new position in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned approximately 0.12% of Anebulo Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 28.40% of the company’s stock.
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.
The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.
See Also
- Five stocks we like better than Anebulo Pharmaceuticals
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
